Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 8/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.53 |
| ▸ | IGF1R | P08069 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30021859 | 0.88 | TAAR1 (0.56) | RIPK1HTTMEN1KMT2AAAK1 | |
| SCHEMBL22049484 | 0.87 | CLK1 (0.46) | STING1RIPK1IGF1RAAK1 | |
| SCHEMBL21988041 | 0.85 | STING1 (0.59) | STING1RIPK1IGF1RHTTRAB9A | |
| SCHEMBL22049401 | 0.85 | RIPK1 (0.60) | RIPK1IGF1RHTTRAB9AMEN1 | |
| SCHEMBL22050814 | 0.85 | CLK1 (0.52) | STING1RIPK1IGF1RAAK1 | |
| SCHEMBL22049571 | 0.84 | STING1 (0.58) | STING1NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL22049591 | 0.84 | STING1 (0.46) | STING1RIPK1IGF1RAAK1 | |
| SCHEMBL22049399 | 0.84 | IGF1R (0.44) | STING1RIPK1IGF1RAAK1 | |
| SCHEMBL22049470 | 0.84 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL30885427 | 0.83 | NTRK1 (0.45) | STING1RIPK1IGF1RNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | STING1 1/4885RIPK1 195/4885IGF1R 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.